Cancer control in the Commonwealth: a roadmap.

Lancet Oncol

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

Published: November 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(24)00591-6DOI Listing

Publication Analysis

Top Keywords

cancer control
4
control commonwealth
4
commonwealth roadmap
4
cancer
1
commonwealth
1
roadmap
1

Similar Publications

A narrative review of sleep and breast cancer: from epidemiology to mechanisms.

Cancer Causes Control

December 2024

Department of Clinical Nutrition, the First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, 230022, Anhui, China.

Breast cancer is the leading cause of cancer-related death and the most common cancer among women worldwide. It is crucial to identify potentially modifiable risk factors to intervene and prevent breast cancer effectively. Sleep factors have emerged as a potentially novel risk factor for female breast cancer.

View Article and Find Full Text PDF

Environmental consequences of petroleum mulch application are crucial in regions prone to wind erosion and desertification. This study aimed to assess the long-term effects of petroleum mulching on soil polycyclic aromatic hydrocarbon (PAH) concentrations and the associated human and ecological risk indices. These indices include incremental lifetime cancer risk (ILCR), hazard index (HI), toxic equivalent concentration (TEQ), toxic unit (TU), and risk quotient (RQ) in soil samples from Khuzestan province, Iran.

View Article and Find Full Text PDF

Background: Patients with cancer are at elevated risk for tuberculosis (TB) reactivation. Diagnosis of latent TB infection and TB disease remains challenging in this patient population despite the advent of interferon-γ release assays (IGRA).

Methods: We retrospectively reviewed medical records of all patients with cancer who had IGRA testing (QuantiFERON-TB [QFT-TB] or T-SPOT.

View Article and Find Full Text PDF

Purpose: No currently available phase III trial compared docetaxel vs. androgen receptor pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Moreover, few is known about the effect of sequential therapies in mHSPC and subsequent metastatic castration resistant prostate cancer (mCRPC).

View Article and Find Full Text PDF

Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma.

Eur J Clin Pharmacol

December 2024

Center for Pharmacometrics, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Shanghai, 201203, China.

Objectives: This study aimed to quantitatively evaluate the efficacy and safety of first-line systemic therapies for treating advanced hepatocellular carcinoma (aHCC).

Methods: The study included clinical trials of first-line systemic therapies for aHCC since the approval of sorafenib in 2007. Hazard function models were used to describe changes in overall survival (OS) and progression-free survival (PFS) over time.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!